Development and validation of the pediatric epilepsy side effects questionnaire

Neurology

Volumn 79, Issue 12, 2012, Pages 1252-1258

  Morita, Diego A ^a   Glauser, Tracy A ^a   Modi, Avani C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ADOLESCENT; AFRICAN AMERICAN; ARTICLE; CAREGIVER; CHILD; CONSTRUCT VALIDITY; CONTROLLED STUDY; EPILEPSY; FEMALE; HAGUE SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PEDIATRIC EPILEPSY SIDE EFFECTS QUESTIONNAIRE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SCORING SYSTEM; TEST RETEST RELIABILITY; TREATMENT DURATION;

EID: 84867546361     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182635b87     Document Type: Article

References (31)

1. Epilepsy Foundation. Incidence and prevalence. Available at: Http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm. Accessed August 17, 2011.
2. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47: 1094-1120.
3. Eadie MJ. Pharmacokinetic principles of drug treatment. In: Shorvon S, Dreifuss F, Fish D, Thomas D, eds. The Treatment of Epilepsy. London: Blackwell Science Ltd.; 1996:138-151.
4. Brown SW, Tomlinson LL. Anticonvulsant side-effects: A self-report questionnaire for use in community surveys. Br J Clin Pract 1982;147-149.
5. Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33:26-37.
6. Baker GA, Frances P, Middleton E, et al. Initial development, reliability, and validity of a patient-based adverse drug event scale. Epilepsia 1994;35:80.
7. Gillham R, Baker G, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res 1996;24:47-55.
8. Aldenkamp AP, Baker GA. The Neurotoxicity Scale-II: Results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Epilepsy Res 1997;27:165-173.
9. Gillham R, Bryant-Comstock L, Kane K. Validation of the Side Effect and Life Satisfaction (SEALS) inventory. Seizure 2000;9:458-463.
10. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: A randomized trial. Neurology 2004;62:23-27.
11. Carpay HA, Arts WF, Vermeulen J, et al. Parentcompleted scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: Development and psychometric analysis. Epilepsy Res 1996;24:173-181.
12. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: A European study. Epilepsia 1997;38:353-362.
13. Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care 1999;37:126-139.
14. Bryant F, Yarnold P. Principal-components analysis and exploratory and confirmatory factor analysis. In: Grimm LG, Yarnold PR, eds. Reading and Understanding Multivariate Statistics. Washington, DC: American Psychological Association; 2001:99-136.
15. Nunnally J, Bernstein I. Psychometric Theory, 3rd ed. New York: McGraw-Hill; 1994.
16. Streiner DL NG. Reliability. In: Health Measurement Scales: A Practical Guide to Their Development and Use. Oxford: Oxford University Press; 1995:104-127.
17. Shrout PE. Measurement reliability and agreement in psychiatry. Stat Methods Med Res 1998;7:301-317.
18. Kunce JT, Cook DW. Random variables and correlational overkill. Educ Psychol Meas 1975;35:529-534.
19. Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associated with the use of antiepileptic drugs: Results from a community-based study. Seizure 2005;14: 198-206.
20. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44(suppl 4):21-29.
21. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: A casecontrol study. Neurology 2003;61:1218-1221.
22. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-a reappraisal. Seizure 1997;6: 121-125.
23. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy: The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995;37:97-108.
24. Moore DC. Body image and eating behavior in adolescents. J Am Coll Nutr 1993;12:505-510.
25. Field AE, Camargo CA Jr, Taylor CB, et al. Overweight, weight concerns, and bulimic behaviors among girls and boys. J Am Acad Child Adolesc Psychiatry 1999;38:754-760.
26. Bourgeois BF. Reducing overtreatment. Epilepsy Res 2002;52:53-60.
27. Cramer JA, Steinborn B, Striano P, et al. Noninterventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand 2011;124:13-21.
28. Modi AC, Guilfoyle SM. Adherence to antiepileptic drug therapy across the developmental life-span. In: Pinikahana J, Walker C, eds. Society, Behaviour and Epilepsy. New York, NY: Nova Science Publishers; 2011:175-205.
29. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415.
30. Guyatt GH. Making sense of quality-of-life data. Med Care 2000;38:II175-179.
31. Pellock JM. Treatment considerations: Traditional antiepileptic drugs. Epilepsy Behav 2002;3:18-23.